Democrat AGs Push for Abortion on Demand With No Limits
Three days after FDA Commissioner Marty Makary promised to “closely monitor the post-marketing safety data on mifepristone for the medical termination of early pregnancy” and a week after National Right to Life wrote Commissioner Makary urging him to reexamine “studies not sponsored by the abortion industry,” four Democrat-led states asked the FDA to remove what pitifully weak “limitations” still exist.
The attorneys general of California, New York, Massachusetts and New Jersey filed a petition Thursday saying the “limitations” are “medically unnecessary.”
The FDA “must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care,” New York Attorney General Letitia James said Thursday, citing the abortion medication’s alleged “25-year safety record.”
Click here to sign up for pro-life news alerts from LifeNews.com
Their strategy was outlined in the always compliant and agreeable New York Times.
“The F.D.A. is required to respond to the petition within 180 days by granting or denying the request, or saying it needs more time,” according to the New York Times’s Pam Belluck. Belluck, who “covers reproductive health,” added, “it would prevent the F.D.A. from changing mifepristone regulations while the petition is pending.”
New Jersey Right to Life Executive Director Marie Tasy blasted state Attorney General Matthew Platkin.
Attorney General Platkin once again prioritizes the interests of the abortion lobby over the safety and well-being of women. The FDA’s decision to review the safety of the abortion pill comes in response to studies revealing severe adverse effects experienced by many women—including sepsis, infection, hemorrhaging, and other serious medical complications within 45 days of taking the drug. Women deserve leaders who advocate for their health and safety, not activist attorneys general who use their office to advance the agenda of the abortion industry.
NRLC writes the FDA
In its letter to Commissioner Makary, NRLC wrote that the FDA had “deregulated” mifepristone “in 2016, 2021, and 2023 so it can now be prescribed online without an in-person physical examination, shipped by mail to women’s homes or made available for pickup at local pharmacies, creating significant concerns over its safety and oversight.”
The letter cited the new study by the Ethics & Public Policy Center (EPPC) which concluded that “10.93 percent of women experienced complications,” 22 times the less-than-one-percent touted by sponsors of the abortion pill.
The letter ended
It isn’t merely that people need assurances that the FDA is ensuring that unsafe, ineffective drugs are kept off the market, but that women are entitled to know the truth about drugs the abortion industry is aggressively, and we believe dishonestly, promoting.
Both mothers and their children need to be protected from false advertising about what these drugs are and what they do. States which wish to protect those women and their unborn children from these dangerous drugs should be able to do so without having to fight the FDA’s official but erroneous assertions of the drug’s safety and efficacy.
Even with its limited reporting and a less than cooperative abortion industry, the FDA itself already knows of at least three dozen deaths and thousands of serious adverse events experienced by American women this past 25 years. Please put an end to this moral and medical travesty before more women and their innocent unborn children die or are injured.
LifeNews.com Note: Dave Andrusko is the editor of National Right to Life News and an author and editor of several books on abortion topics. He frequently writes Today’s News and Views — an online opinion column on pro-life issues.
The post Democrat AGs Push for Abortion on Demand With No Limits appeared first on LifeNews.com.